Clinuvel Pharmaceuticals (ASX:CUV) said four patients with darker skin types enrolled in its study of drug candidate Scenesse in the treatment of vitiligo reported satisfaction with the treatment, which was also well tolerated, according to a Thursday filing with the Australian bourse.
The patients had received seven implants of the drug candidate and up to 40 adjunct narrowband ultraviolet B phototherapy sessions, the filing said.
Shares of the company rose 2% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.